Vaccine Therapy and GM-CSF in Treating Patients With Progressive Non-Hodgkin's Lymphoma

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed follicular B-cell non-Hodgkin's lymphoma (NHL)
• * Grade 1, 2, or 3
• Progressive disease AND did not receive autologous immunoglobulin idiotype-KLH conjugate vaccine (FavId™) while enrolled on protocol FAV-ID-06
• Meets 1 of the following criteria:
• * Received salvage therapy after completion of protocol FAV-ID-06
• * At least 4 weeks, but no more than 4 months, since prior salvage therapy
• * Did not receive salvage therapy after completion of protocol FAV-ID-06
• * At least 4 weeks, but no more than 4 months, since completion of prior treatment on protocol FAV-ID-06
• No history of CNS lymphoma OR meningeal lymphomatosis
• PATIENT CHARACTERISTICS:
• Age
• 18 and over
• Performance status
• ECOG 0-2
• Life expectancy
• Not specified
• Hematopoietic
• Not specified
• Hepatic
• Not specified
• Renal
• Not specified
• Cardiovascular
• No history of congestive heart failure
• Pulmonary
• No history of compromised pulmonary function
• Other
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• HIV negative
• No active bacterial, viral, or fungal infection
• No psychiatric disorder
• No other serious nonmalignant disease that would preclude study participation
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• See Disease Characteristics
• No prior allogeneic transplantation\*
• No prior rituximab regimen\* other than that administered on protocol FAV-ID-06 (rituximab 375 mg/m\^2 IV weekly for 4 weeks)
• Chemotherapy
• No prior purine analogues\* (e.g., fludarabine or cladribine)
• Endocrine therapy
• No prior or concurrent steroids (e.g., steroid doses in excess of daily replacement)
• Radiotherapy
• Not specified
• Surgery
• Not specified
• Other
• Recovered from prior salvage therapy
• No prior or concurrent immunosuppressive therapy
• No prior investigational agents\*
• No other concurrent antilymphoma therapy NOTE: \*As salvage therapy administered between completion of protocol FAV-ID-06 and enrollment onto this study